Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer
| Autor: | Daniel Sattler, Angela Ihbe-Heffinger, Nadia Harbeck, Stefan Wagenpfeil, Ulrike Nitz, Rudolf Bernard, Volker R. Jacobs, Michael Braun, Walther Kuhn |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Anthracycline Cyclophosphamide medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Docetaxel Breast cancer Internal medicine Germany Antineoplastic Combined Chemotherapy Protocols Adjuvant chemotherapy Cost analysis Health resources Breast neoplasm Prevalence Medicine Humans Anthracyclines Chemotherapy Taxane business.industry Hematology General Medicine Health Care Costs Middle Aged medicine.disease Confidence interval ddc Regimen Methotrexate Treatment Outcome Chemotherapy Adjuvant Female Taxoids Fluorouracil Cisplatin business medicine.drug |
| Zdroj: | Onkologie. 32(8-9) |
| ISSN: | 1423-0240 |
| Popis: | Background: Taxane-based adjuvant chemotherapy is the current standard for node-positive breast cancer patients. Recent data identified relevant patient subgroups with questionable benefit. To estimate the incremental burden on health care resources and costs, we compared a modern sequential regimen (4×epirubicin/cyclophosphamide; 4×docetaxel: EC→DOC) to CMF. Patients and Methods: Data were obtained alongside the phase III WSG-AGO Intergroup trial (2000–2005). A cohort of 110 patients receiving 1,047 chemotherapy cycle days at 38 study sites was analyzed from a hospital perspective. Results: Mean age was 52.4 years. Mean costs for the EC→DOC group (n = 54) totaled €8,459 per patient (95% confidence interval (CI): €7,785–9,132) with cytostatic drug costs being the largest burden (€5,673; 67%). CMF was significantly (–41.2%) less expensive (€4,973; 95% CI: €4,706–5,240), and toxicity-associated rehospitalization was reduced by half (CMF: n = 4, EC→DOC:n =8). Conclusions: Our results demonstrate a substantial budget increase attributable to introduction of taxanes to adjuvant chemotherapy of breast cancer. Data will allow estimating cost-effectiveness of individualized chemotherapy strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|